Decreased miR-29b/c in GC tissue samples. by He Cui (229445)

The rate of lariat formation is decreased two-fold by isoginkgetin treatment. by Jesse M. Gray (527662)

“…(<b>C</b>) Isoginkgetin treatment leads to a decreased rate of lariat formation (* indicates <i>p</i> = 0.02) without affecting exon ligation or excised lariat degradation (<i>p</i> = 0.22, 0.08), with calculations as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0089673#pone-0089673-g001" target="_blank">Fig. 1</a>. …”

LOH resulting in 189R/R produces a strong decrease in drug susceptibility. by Pétra Vande Zande (17628246)

FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells. by Laura L. Stafman (6577184)

Subjects:

The decrease in c-Myc protein levels in A549 cells was primarily due to proteasomal degradation. by Qin Li (36669)

Decreasing fluconazole susceptibility of clinical South African <i>Cryptococcus neoformans</i> isolates over a decade by Serisha D. Naicker (8648370)

Identification of proteins that presented a significant decrease in their expression content. by Rubens D. M. Magalhães (395962)

Beta-catenin signaling is decreased in intermediate progenitor cells. by Christopher A. Mutch (243132)

“…<p>(<b>A</b>) Cortex from E14.5 Axin2-d2EGFP transgenic mice stained for GFP (green), Tbr2 (red), and DNA (blue). …”

Hepatic Expression of Detoxification Enzymes Is Decreased in Human Obstructive Cholestasis Due to Gallstone Biliary Obstruction by Jin Chai (183630)

“…</p><p>Conclusions</p><p>The levels of hepatic detoxification enzymes were significantly decreased in human obstructive cholestasis, and these decreases were positively associated with a marked reduction of FXR levels. …”

a-f. PSP significantly decreased NP-specific IgM responses at days 4 and 21 compared to ACACIA. by Bhagwant Kaur Sekhon (847697)

Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis by Raj Vuppalanchi (458660)

“…Notably, miR-155, a known regulator of liver inflammation, had the highest fold increase in cirrhotic livers (2.2-fold, P=4.16E-08) and significantly correlated with hepatic CYP3A activity (r=-0.50, P=0.017). …”

Mesothelin expression and RG7787 uptake is decreased in KLM-1-R. by Kevin Hollevoet (710450)

“…<p><b>A</b>: Surface mesothelin levels are 5-fold lower in resistant KLM-1 (KLM-1-R) compared to KLM-1. …”

Resveratrol decreases PKM2 expression. by Mohd Askandar Iqbal (324124)

“…<p>Resveratrol treatment decreases PKM2 mRNA in (A), HeLa; (B), HepG2 and (C), MCF-7; by approximately two-folds. β-actin was taken as endogenous control and normalized to PKM2 mRNA. …”

PTH decreased cell apoptosis in a Flt-3L expanded population. by Flavia Q. Pirih (360515)

TUDCA decreases ER stress in HOX neonatal rat lungs. by Kirkwood A. Pritchard Jr. (13449794)

“…<p>(<b>A</b>) The expression levels of ER stress markers (P-PERK 0.6±0.1-fold, p<0.001, n = 5; PERK 0.7±0.1-fold, p = 0.00364, n = 5; P-IRE1α 0.6±0.0-fold, p<0.001, n = 5; IRE1α 0.6±0.1-fold, p<0.001, n = 5; GRP78 0.8±0.1-fold, p<0.001, n = 5; cleaved ATF6 0.1±0.0-fold, p<0.001, n = 5; spliced XBP1 0.3±0.0-fold, p<0.001, n = 5; 2 males and 3 females) are all decreased while the N-glycosylated VEGFR2 is increased (3.5±0.2-fold, p<0.001, n = 5) in HOX neonatal lungs at P10 indicating TUDCA can attenuate hyperoxia-induced ER stress. …”

Binding sites decrease the barrier to folding in hisactophilin. by Shachi Gosavi (160132)

The functional half-life of WNV decreases in the presence of virus-specific antibody. by Kimberly A. Dowd (129927)

ETHE1-p.Arg163Gln and p.Arg163Trp are folded but have decreased stability. by Bárbara J. Henriques (627180)

Subset of selected genes showing a ≥2-fold change decrease of expression in the <i>furA</i>-turning off strain AGcoaRFurA. by Andrés González (767802)

“…<p>Subset of selected genes showing a ≥2-fold change decrease of expression in the <i>furA</i>-turning off strain AGcoaRFurA.…”

miR-100 decreases tumor size. by Bahauddeen M. Alrfaei (484859)